| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| 25mg | |||
| Other Sizes |
| Targets |
Interleukin-17 (IL-17) receptor or its downstream signaling components. IL-17 modulator 4 is a tool compound used to modulate the IL-17 pathway. By blocking IL-17 signaling, it can reduce the production of pro-inflammatory cytokines and chemokines.
|
|---|---|
| ln Vitro |
IL-17 modulator 4 has demonstrated activity in modulating the IL-17 pathway in vitro. It can inhibit IL-17-induced signaling in cell-based assays, such as the activation of NF-κB and the production of inflammatory mediators. Its potency and selectivity have been characterized.
|
| ln Vivo |
In vivo, IL-17 modulator 4 has been studied in animal models of inflammatory and autoimmune diseases. It has been shown to reduce inflammation and disease severity in models of psoriasis, rheumatoid arthritis, and other conditions.
|
| Enzyme Assay |
In vitro receptor binding assays for IL-17 modulator 4 involve measuring its affinity for the IL-17 receptor using radioligand binding techniques or surface plasmon resonance. Membranes from cells expressing the IL-17 receptor are incubated with labeled IL-17 and increasing concentrations of the compound.
|
| Cell Assay |
Cellular assays for IL-17 modulator 4 involve treating cells with the compound and measuring IL-17-induced signaling, such as NF-κB activation or cytokine production. The compound's ability to inhibit these responses is assessed.
|
| Animal Protocol |
In vivo animal studies for IL-17 modulator 4 typically involve administration to rodent models of inflammatory diseases. Efficacy is assessed by measuring clinical scores, histopathology, and inflammatory markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for IL-17 modulator 4 is limited. As a research compound, its properties such as bioavailability and half-life are typically characterized in preclinical studies.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of IL-17 modulator 4 are limited. As a research tool, its safety profile is primarily assessed in the context of in vivo efficacy studies.
|
| References | |
| Additional Infomation |
IL-17 modulator 4 is a research compound used to study the role of the IL-17 pathway in inflammatory and autoimmune diseases. It is a valuable tool for investigating the therapeutic potential of targeting IL-17 signaling.
|
| Molecular Formula |
C27H34N6O2
|
|---|---|
| Molecular Weight |
474.60
|
| Exact Mass |
474.27
|
| Elemental Analysis |
C, 68.33; H, 7.22; N, 17.71; O, 6.74
|
| CAS # |
2446803-65-0
|
| Related CAS # |
IL-17 modulator 1 disodium;2446803-91-2;(R)-IL-17 modulator 4;2446804-29-9;IL-17 modulator 1;2446803-85-4;IL-17 modulator 4 sulfate;2446806-90-0
|
| PubChem CID |
153616520
|
| Appearance |
Off-white to gray solid powder
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
35
|
| Complexity |
749
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N1(C(C)C)C(C(N[C@H](C(NC2=CC=C(C3=C(C)NN=C3C)C=C2)=O)C(C2CC2)C2CC2)=O)=CC=N1
|
| InChi Key |
CQKVACARDGYEMU-VWLOTQADSA-N
|
| InChi Code |
InChI=1S/C27H34N6O2/c1-15(2)33-22(13-14-28-33)26(34)30-25(24(19-5-6-19)20-7-8-20)27(35)29-21-11-9-18(10-12-21)23-16(3)31-32-17(23)4/h9-15,19-20,24-25H,5-8H2,1-4H3,(H,29,35)(H,30,34)(H,31,32)/t25-/m0/s1
|
| Chemical Name |
N-[(2S)-1,1-dicyclopropyl-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-3-oxopropan-2-yl]-2-propan-2-ylpyrazole-3-carboxamide
|
| Synonyms |
IL-17 modulator 4; CVN03650; CVN 03650; CVN 03650;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~300 mg/mL (~632.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 7.5 mg/mL (15.80 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1070 mL | 10.5352 mL | 21.0704 mL | |
| 5 mM | 0.4214 mL | 2.1070 mL | 4.2141 mL | |
| 10 mM | 0.2107 mL | 1.0535 mL | 2.1070 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
